Blood Coagulation Disorder
Conditions
Brief summary
Palonosetron may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of palonosetron. The investigators therefore will perform the present study to measure the effect of palonosetron levels using thromboelastography.
Interventions
DRUG0 ul of palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
DRUG1 ul of palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
DRUG10 ul of palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
DRUG100 ul of palonosetron
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
Sponsors
Seoul National University Bundang Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers * Age: 20 to 65 years * Body weight \> 50 kg * Volunteers who provided informed consent
Exclusion criteria
* Hematologic disease * Anticoagulant medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Citrated Functional Fibrinogen | During the thromboelastography analysis/ an average of 1 hour | Provides clot strength based on fibrinogen contribution |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Citrated Kaolin Heparinase | During the thromboelastography analysis/ an average of 1 hour | To assess the effect of heparin |
| Citrated Rapid Thromboelastography | During the thromboelastography analysis/ an average of 1 hour | A quicker assessment of clot strength, without assessment of clot initiation |
| Heparinized Kaloin Heprinase | During the thromboelastography analysis/ an average of 1 hour | To measure the platelet function |
| Citrated Kaolin | During the thromboelastography analysis/ an average of 1 hour | Normal thromboelastography |
| Adenosine diphosphate | During the thromboelastography analysis/ an average of 1 hour | To measure the drug effect |
| Arachidonic acid | During the thromboelastography analysis/ an average of 1 hour | To measure the drug effect |
| Activator F | During the thromboelastography analysis/ an average of 1 hour | To elimitate the platelt function |
Countries
South Korea
Contacts
Primary ContactHyo-Seok Na, MD., PhD.
Outcome results
None listed